Relationship between baseline or time-varying characteristics and interval (days) between viral load measurements on multivariable mixed model analysis^a.

<p>The intercept represents the average interval for a non-MSM who is a seafarer, lives ≥160 kilometers from Zagreb, has high school or lower education, has had at least one CART change, is taking a non-NNRT regiment, has a CD4 cell count of 350 per µL, is treated in 2008/09 and has a follow-up time of 2 years.</p>a<p>Adjusted for the linear and quadratic term of time.</p>b<p>Least square means estimates from the model.</p>c<p>When 47 potential outlying observations were removed the result became insignificant (p = 0.376).</p><p>MSM, men who have sex with men; CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor.</p

Comparison of baseline demographics and clinical characteristics according to frequency of viral load testing.

<p>Standard, subjects having <50% of measurements <5 months apart. Less frequent, subjects having ≥50% of measurements >5 months apart.</p><p>Values are N (%) or median (interquartile range).</p><p>MSM, men who have sex with men; CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</p

Rate of viral load tests per one year according to different baseline patients characteristics.

<p>95% confidence intervals are in parenthesis.</p>a<p>Men who had sex with men <i>versus</i> other categories.</p>b<p>NNRT-based compared to PI-based.</p><p>VL, viral load; CART, combination antiretroviral therapy; NNRT, non-nucleoside reverse transcriptase inhibitor;</p><p>PI, protease inhibitor; NRT, nucleoside analogue reverse transcriptase inhibitor.</p

Relationship between baseline or time-varying characteristics and interval (days) between viral load measurements using crude mixed model analysis.

a<p>Adjusted for the linear and quadratic term of time and one independent variable.</p>b<p>Least square means estimates from the model. MSM, men who have sex with men;</p><p>CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor;</p><p>PI, protease inhibitor.</p

Prevalence of HIV by indicator condition.

*<p>Unpublished prevalence data from participating study sites.</p>**<p>includes MSM, IDU prevalence.</p>***<p>UNAIDS adults aged 15–49 country HIV prevalence rate <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052845#pone.0052845-UNAIDS2" target="_blank">[31]</a>.</p

Prevalence of HIV-positive test by ethnicity and region.

<p>Prevalence of HIV-positive test by ethnicity and region.</p

Patient characteristics by European region.

1<p>North:Denmark, Sweden, Netherlands, UK, West Central: Austria, Belgium, Germany, East Central: Belarus, Bosnia, Croatia, Poland, Ukraine and South: Italy and Spain.</p>2<p>IQR:Interquartile range.</p>3<p>STI: Sexually transmitted infection, LYM: Malignant lymphoma, CAN: Cervical or anal cancer/dysplasia, HZV: Herpes zoster, HEP: Hepatitis B or C, MON: Ongoing mononucleosis-like illness, CYT: Unexplained leukocytopenia/thrombocytopenia lasting >4 weeks, SEB: Seborrheic dermatitis/exanthema (SEB).</p><p>Missing data: 10 (0.3%) gender, 120 (3.3%) ethnicity, 63 (1.8%) age, 120 (3.3%) sexual orientation, 291 (8.1%) previous HIV test.</p